Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
McKesson
Express Scripts
Harvard Business School
Boehringer Ingelheim

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,568,766

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,568,766
Title:Peptides and peptide mimetics to treat pathologies associated with eye disease
Abstract: This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection.
Inventor(s): Anantharamaiah; Gattadahalli M. (Birmingham, AL), Fogelman; Alan M. (Beverly Hills, CA), Navab; Mohamad (Los Angeles, CA), Rudolf; Martin (Lubeck, DE)
Assignee:
Application Number:12/027,728
Patent Claims:1. A method for treating a subject with eye disease, the method comprising administering to the subject in need thereof an effective amount of one or more of the active agents described in SEQ ID NOS: 1-1208 in an amount sufficient to ameliorate one or more symptoms of said condition.

2. The method of claim 1, wherein said active agent is a polypeptide comprising the amino acid sequence of 4F (SEQ ID NO:5).

3. The method of claim 1, wherein said administration is by a route selected from the group consisting of oral administration, nasal administration, rectal administration, intraperitoneal injection, and intravascular injection, intraocular injection, intravitreal injection, subconjuctival injection, peri-retrobulbar injection, subcutaneous injection, eye drops, eye gel, eye ointment, spray, emulsion, suspension, transcutaneous administration, and intramuscular injection, drug carriers, sponges, contact lenses, polymers, microspheres, implants, pellets, and genetically engineered cells.

4. The method of claim 1, wherein said active agent is administered in conjunction with a antiangiogenic agents.

5. The method of claim 1, wherein the eye disease is selected from the group consisting of macular degeneration, age related maculopathy (ARM), dry age related macular degeneration (AMD), wet age related macular degeneration, glaucoma, ocular hypertension, macular edema, retinal pigment epithelium detachments, Coat's disease, uveitis, sicca syndrome, hereditary diseases associated with increased extracellular or intracellular lipid storage or accumulation, and juvenile macular degeneration.

6. A method of ameliorating a symptom of eye disease, the method comprising a) administering to the subject an effective amount of a peptide wherein said peptide ranges in length from about 18 to 37 amino acids and comprises at least 3 alanines (A), 2 aspartates (D), 2 glutamates (E), 4 phenylalanines (F), 4 lysines (K), 1 valine (V), 1 tryptophan (W), 1 tyrosine (Y); b) wherein said peptide forms a class A amphipathic helix; c) comprises at least one "D" amino acid residue; and d) protects a phospholipid against oxidation by an oxidizing agent.

7. The method of claim 6, wherein said peptide further comprises a protecting group coupled to the amino or carboxyl terminus.

8. The method of claim 6, wherein said peptide further comprises a first protecting group coupled to the amino terminus and a second protecting group coupled to the carboxyl terminus.

9. The method of claim 7, wherein said protecting groups are independently selected from the group consisting of acetyl, amide, and 3 to 20 carbon alkyl groups, Fmoc, Tboc, 9-fluoreneacetyl group, 1-fluorenecarboxylic group, 9-florenecarboxylic group, 9-fluorenone-1-carboxylic group, benzyloxycarbonyl, Xanthyl (Xan), Trityl (Trt), 4-methyltrityl (Mtt), 4-methoxytrityl (Mmt), 4-methoxy-2,3,6-trimethyl-benzenesulphonyl (Mtr), Mesitylene-2-sulphonyl (Mts), 4,4-dimethoxybenzhydryl (Mbh), Tosyl (Tos), 2,2,5,7,8-pentamethyl chroman-6-sulphonyl (Pmc), 4-methylbenzyl (MeBzl), 4-methoxybenzyl (MeOBzl), Benzyloxy (BzlO), Benzyl (Bzl), Benzoyl (Bz), 3-nitro-2-pyridinesulphenyl (Npys), 1-(4,4-dimentyl-2,6-diaxocyclohexylidene)ethyl (Dde), 2,6-dichlorobenzyl (2,6-DiCl-Bzl), 2-chlorobenzyloxycarbonyl (2-Cl-Z), 2-bromobenzyloxycarbonyl (2-Br-Z), Benzyloxymethyl (Bom), t-butoxycarbonyl (Boc), cyclohexyloxy (cHxO), t-butoxymethyl (Bum), t-butoxy (tBuO), t-Butyl (tBu), Acetyl (Ac), and Trifluoroacetyl (TFA).

10. The method of claim 6, wherein all enantiomeric amino acids are "D" amino acids.

11. The method of claim 6, wherein said peptide is mixed with a pharmacologically acceptable excipient.

12. The method of claim 6, wherein said peptide is mixed with a pharmacologically acceptable excipient suitable for oral administration to a mammal.

13. The method of claim 6, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1191, SEQ ID NO: 1192, SEQ ID NO: 1193, SEQ ID NO: 1194, SEQ ID NO: 1195, SEQ ID NO: 1196, SEQ ID NO: 1197, and the reverse of any of these sequences.

14. The method of claim 13, wherein said peptide comprises a protecting group coupled to the amino terminal and said amino terminal protecting group is a protecting group selected from the group consisting of acetyl, propionyl, and a 3 to 20 carbon alkyl.

15. The method of claim 13, wherein said peptide comprises a protecting group coupled to the carboxyl terminal and said carboxyl terminal protecting group is an amide.

16. The method of claim 13, wherein said peptide comprises a first protecting group coupled to the amino terminus wherein said protecting group is a protecting group selected from the group consisting of acetyl, propionyl, and a 3 to 20 carbon alkyl; and a second protecting group coupled to the carboxyl terminal and said carboxyl terminal protecting group is an amide.

17. The method of claim 6, wherein said oxidizing agent is selected from the group consisting of hydrogen peroxide, 13(S)-HPODE, 15(S)-HPETE, HPODE, HPETE, HODE, and HETE.

18. The method of claim 6, wherein said phospholipid is selected from the group consisting of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (Ox-PAPC), 1-palmitoyl-2-oxovaleroyl-sn-glycero-3-phosphorylcholine (POVPC), 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine (PGPC), 1-palmitoyl-2-epoxyisoprostane-sn-glycero-3-phosphorylcholine (PEIPC), 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (SAPC), 1-stearoyl-2-oxovaleroyl-sn-glycero-3-phosphorylcholine (SOVPC), 1-stearoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine (SGPC), 1-stearoyl-2-epoxyisoprostane-sn-glycero-3-phosphorylcholine (SEIPC), 1-stearoyl-2-arachidonyl-sn-glycero-3-phosphorylethanolamine (Ox-SAPE), 1-stearoyl-2-oxovaleroyl-sn-glycero-3-phosphorylethanolamine (SOVPE), 1-stearoyl-2-glutaroyl-sn-glycero-3-phosphorylethanolamine (SGPE), and 1-stearoyl-2-epoxyisoprostane-sn-glycero-3-phosphorylethanolamine (SEI PE).

19. A method for treating a subject with eye disease, the method comprising administering to the subject in need thereof an effective amount of one or more of the active agents described in SEQ ID NOS: 1-1208 in an amount sufficient to ameliorate one or more symptoms of said condition in combination with an anti-angiogenic therapy.

20. The method of claim 19, wherein the anti-angiogenic therapy is selected from the group consisting of pegaptanib, ranibizumab, bevacizumab, carboxyamidotriazole, TNP-470, CM101, IFN-.alpha., IL-12, platelet factor 4, suramin, SU5416, thrombospondin, VEGFR antagonists, angiostatic steroids and heparin, cartilage-derived angiogenesis inhibitory factor, matrix metallopreteinase inhibitors, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, prolactin, .alpha..sub.v.beta..sub.3 inhibitors, linomide, VEGF-Trap, aminosterols, cortisone, tyrosine kinase inhibitors, anti-angiogenic siRNA, inhibitors of the complement system, and gentherapeutic therapies.

21. A method of ameliorating a symptom of eye disease, the method comprising administering to the subject in need thereof an effective amount of one or more of the active agents described in SEQ ID NOS: 1-1208 in an amount sufficient to ameliorate one or more symptoms of said condition in combination with an anti-angiogenic therapy.

22. The method of claim 21, wherein the anti-angiogenic therapy is selected from the group consisting of pegaptanib, ranibizumab, bevacizumab, arboxyamidotriazole, TNP-470, CM101, IFN-.alpha., IL-12, platelet factor 4, suramin, SU5416, thrombospondin, VEGFR antagonists, angiostatic steroids and heparin, cartilage-derived angiogenesis inhibitory factor, matrix metallopreteinase inhibitors, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, prolactin, .alpha.v.beta.3 inhibitors, linomide, VEGF-Trap, aminosterols, cortisone, tyrosine kinase inhibitors, anti-angiogenic siRNA, inhibitors of the complement system, and gentherapeutic therapies.

23. The method of claim 10 wherein the symptom is selected from the group consisting of accumulation of extracellular lipids in Bruch's membranes, accumulation of lipid rich debris, vision loss, formation of choriocapillaris, thickening of the Bruch's membrane, accumulation of neutral lipids in the Bruch's membrane, formation of a diffusion barrier between the retinal pigment epithelium and choriocapillaris, deposition of debris (basal linear deposits and drusen) between the basal membrane of the RPE and the inner collagenous layer, accumulation of lipofuscin in the RPE cells, RPE atrophy, photoreceptor degeneration, choroidal neovascularization, as well as leakage, bleeding, and scarring of the eye.

24. The method of claim 10, wherein the eye disease is selected from the group consisting of macular degeneration, age related maculopathy (ARM), dry age related macular degeneration (AMD), wet age related macular degeneration, glaucoma, ocular hypertension, macular edema, retinal pigment epithelium detachments, Coat's disease, uveitis, sicca syndrome, hereditary diseases associated with increased extracellular or intracellular lipid storage or accumulation, and juvenile macular degeneration.

Details for Patent 8,568,766

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Request a Trial 2020-08-24 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Request a Trial 2020-08-24 RX search
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30   Request a Trial 2020-08-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,568,766

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
AstraZeneca
Express Scripts
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.